Ranking | Drug | Motility reduction after 3 daysa | Motility reduction (%) after 5 daysa | Summary statistics for CR50 | ||||||
---|---|---|---|---|---|---|---|---|---|---|
1.25 μg/ml | 10 μg/ml | 1.25 μg/ml | 10 μg/ml | Mean ± SD | Median | Geometric mean | Interquartile range | 95% CI | ||
1 (Highly effective) | MFQ | 1.8 | 100 | 9.3 | 100 | 3.9 ± 0.1 | 3.8 | 3.9 | 0.16 | 3.7–4.0 |
AMQ | 2.7 | 70.6 | 29.8 | 95.1 | 4.1 ± 0.1 | 4 | 4.1 | 0.1 | 4.0–4.1 | |
2 | CQ | 3.7 | 10.3 | 31.3 | 63.3 | 8 ± 0.2 | 8 | 8 | 0.37 | 7.7–8.3 |
H-FLBZ | 7 | 36.8 | 0.9 | 42.5 | 8.1 ± 0.7 | 8.1 | 8 | 1.36 | 6.9–9.3 | |
IVM | 2 | 24.4 | 5 | 50.6 | 8.7 ± 0.5 | 8.6 | 8.7 | 0.83 | 8.1–9.3 | |
ATS | 0.3 | 5.6 | 6.5 | 45.4 | 9.9 ± 1.4 | 10.1 | 9.8 | 2.58 | 7.7–12.1 | |
3 | QN | 0.4 | 36.4 | 2.7 | 36.5 | 12.7 ± 0.9 | 12.9 | 12.7 | 1.65 | 11.8–13.6 |
GLV | 0.5 | 25.2 | 1.3 | 42.1 | 13.4 ± 2.6 | 12.8 | 13.2 | 4.64 | 9.3–17.5 | |
4 | R-FLBZ | 0.6 | 24.2 | 10.2 | 25.8 | 17.6 ± 3 | 17.8 | 17.5 | 5.56 | 12.9–22.4 |
FLBZ | 7.2 | 18.5 | 12.9 | 25.3 | 21.2 ± 3.2 | 21.2 | 21 | 5.79 | 16.1–26.3 | |
SCYX-7851 | 0.1 | 18.1 | 1 | 31.4 | 25.4 ± 5.6 | 24.6 | 24.9 | 10.64 | 20.3–30.6 | |
5 (Not effective) | PZQ | 0.2 | 3.1 | 2.1 | 3.5 | – | – | – | – | – |
Fexinidazole | 0.4 | 0.6 | 1.6 | 2.6 | – | – | – | – | – |